Is This Low-Debt Stock Ready for the Next Leg?

. is a pharmaceutical company primarily engaged in the production and distribution of a broad range of pharmaceutical products. This includes generic formulations, injectables, and over-the-counter medications. What Makes Caplin Point Interesting? The company has delivered 19.6% quarterly revenue growth and 15.8% annual earnings growth, with TTM revenue of around ₹2,287 crore. Profitability is another major strength: Operating margin: 31.43% Profit margin: 29.09% Quarterly revenue growth: 19.6% Annual earnings growth: 15.8% The Balance Sheet Stands Out One of the biggest positives is Caplin Point's relatively low leverage and strong liquidity. Debt-to-equity: 0.13 Current ratio: 6.70 Cash: ~₹1,007 crore This provides the company with significant financial flexibility to fund future expansion. Where Could the Growth Come From? Caplin Point's focus on emerging markets such as Latin America, Africa and Southeast Asia provides an important growth opportunity. Its portfolio across generic formulations, injectables and OTC products also gives the company exposure to multiple pharmaceutical segments. The combination of double-digit growth, strong margins, low debt and a healthy cash position makes Caplin Point an interesting pharma stock to track. The valuation isn't cheap at a TTM P/E of 30.66x, but the forward P/E of 24.19x and PEG of 1.37 suggest that a portion of the premium valuation is supported by expected earnings growth. Technically, the stock is also close to its 52-week high of ₹2,750 and trades well above its 50-day and 200-day moving averages, indicating strong momentum.